advisory or consulting fees and/or other support from Aadvarak Therapeutics, Abbvie, Adarx, Altasciences, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Baim Institute, Bain Capital, Bayer, Betagenon, Bioio, Biomea, Boehringer-Ingelheim, Boston Scientific, Carmot, Corxel, Cytoki Pharma, Eli Lilly, Genentech, Janssen/J&J, Juvena, Kailera Therapeutics, Keros Therapeutic, Mediflix, Metsera, Neurocrine, Novo Nordisk, Penguin Bio, Pfizer, Regeneron, Response Pharmaceutical, Roche, Sanofi, Shionogi, Sparrow, Skye Bioscience, Source Bio, Structure Therapeutics, SUMMIT, Tenvie, TERNS Pharma, Verdiva Bio, Viking Therapeutics and Zealand Pharma
References: Mark Heffernan, Roger J
It improves mood
Researchers asking what happened to Amino Asylum should treat the company as permanently closed and identify alternative suppliers
First things first: what is retatrutide
They have compared the GLP-1 agonist to bupropion-naltrexone, an older class of weight-loss medication